Jeffrey Holiday
About Jeffrey Holiday
Jeffrey Holiday is the Director of Allogeneic Operations at Adaptimmune, where he has worked since 2021. He has a background in cellular and molecular biology and has held various roles in the pharmaceutical industry, including positions at GSK and MSD Sharp & Dohme GmbH.
Current Role at Adaptimmune
Jeffrey Holiday serves as the Director of Allogeneic Operations at Adaptimmune, a position he has held since 2021. In this role, he is responsible for overseeing the operations related to allogeneic therapies. His work is based in Oxfordshire, England, where he contributes to the development and implementation of innovative treatment solutions.
Previous Experience at Adaptimmune
Prior to his current role, Jeffrey Holiday worked at Adaptimmune as an Associate Director from 2019 to 2021. During this time, he focused on advancing the company's operational capabilities and supporting the development of cellular therapies. His tenure at Adaptimmune provided him with significant experience in the field of immunotherapy.
Experience at GSK
Jeffrey Holiday has extensive experience at GSK, where he held multiple positions. He served as a Validation Leader from 2014 to 2015, followed by a role as Validation Manager (Process & Cleaning) from 2015 to 2017. He then transitioned to Operations Support Manager (OSD small scale & NPI) from 2017 to 2019. His roles at GSK were primarily based in Ware, Hertfordshire, and involved ensuring compliance and operational efficiency.
Educational Background
Jeffrey Holiday studied at the University of Cape Town, where he earned a BSc (Hons) in Cell/Cellular and Molecular Biology from 2004 to 2007. He also attended Fairbairn College from 1999 to 2003, completing his secondary education. His academic background has provided a strong foundation for his career in the biotechnology and pharmaceutical sectors.
Early Career at MSD Sharp & Dohme GmbH
Jeffrey Holiday began his career at MSD Sharp & Dohme GmbH, where he worked as a Technician specializing in fermentation from 2008 to 2012. This role allowed him to gain hands-on experience in bioprocessing, which has been beneficial throughout his subsequent positions in the industry.